IO Frontiers World 2019


Eric Ahrens

Prof Eric Ahrens

Professor of Radiology, University of California San Diego

Dr. Ahrens’ research involves imaging innovations and adapting MRI to visualize molecular and cellular events in vivo. Currently, Ahrens is a Professor in the Department of Radiology at the University of California San Diego, Director of Stem Cell Molecular Imaging at the Sanford Consortium for Regenerative Medicine, and Director of the Molecular Imaging Center at Stanford. Formally, he was a Professor of Biological Sciences at Carnegie Mellon University. He has also served as a senior research fellow in the Department of Biology, California Institute of Technology. He holds a Ph.D. in physics from the University of California at Los Angeles and was a graduate fellow at Los Alamos National Laboratory. Ahrens is engaged in the design, characterization and application of novel contrast agents for clinical cell tracking and visualizing gene expression using MRI. He has pioneered the use of fluorine-19 probes for clinical cell tracking and has published widely on spin physics, imaging probe development, in vivo imaging in animal models using high-field MRI, and the conduct of clinical trials. He is an inventor on 9 patents related to MRI. In 2005, Dr. Ahrens founded the biotechnology company Celsense, Inc. to translate imaging probe inventions born from his laboratory and to disseminate imaging probes to the biomedical community.

  • "Great venue to solidify and harmonize on the current challenges facing this sector - in real time. The caliber of the speakers and session contents was premier. “
    Dolores Baksh
    Innovation Leader, GE Healthcare
  • “A great event to learn about the hurdles that are needed to be overcome to get through the clinic.”
    Devin Bridgen
    Scientist, strategic partnerships, SQZ Biotech
  • "It was a great opportunity to share current data and thinking about the development of therapeutics directed at modulating the immune response to cancer."
    Lance Leopold
    Vice President, Head of Oncology Development, Incyte Corporation
  • "Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field."
    Dr James Trager
    Vice President, Research & Product Development, Dendreon
  • “In the rapidly moving Advanced Therapy market, Phacilitate remains one of the premier events.”
    David James
    CEO, Scinogy